155 Reasons for stopping MS disease modifying treatment in a UK cohort

Résumé fourni par la source

Background Success of disease modifying therapy (DMT) for relapsing MS (RMS) is dependent on both effectiveness and adherence. We have explored reasons for stopping DMT in a large multicentre RMS cohort to inform disease management. Methods Data was collected from sequential RMS patients receiving a DMT in 8 UK MS centres. DMT discontinuation events were recorded according to a standardised classification comprising: adverse event, increased risk of adverse event, lack of efficacy, onset of progressive disease, patient choice, pregnancy/pre-conceptual care, other, unknown. Results Data from 6,816 prescriptions in 4,102 patients (female 72%, mean 1.7 prescriptions, range 1-6 per patient) were analysed. The most common reason for stopping was lack of efficacy (37%) followed by adverse event (31%), increased risk of adverse event (10%) and then pregnancy/preconceptual care (9%). Reasons for stopping varied by treatment duration, age, sex and DMT. DMT discontinuation due to adverse events fell from 51% in year 1, to 15% in years 5-10; discontinuation due to lack of efficacy rose from 22% to 45%. Increasing disability was rarely a reason to stop DMT. Conclusions These data provide valuable insights into the real-world utility of MS DMTs and could provide a rationale to refine existing treatment pathways.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.